```html

Lepromatous Leprosy – Comprehensive Medical Guide

Overview

Lepromatous leprosy is the most severe and contagious form of leprosy (also known as Hansen’s disease). It is caused by the bacterium Mycobacterium leprae or, more rarely, Mycobacterium lepromatosis. In lepromatous disease, the immune system fails to mount an effective cell‑mediated response, allowing the bacteria to multiply widely in the skin, peripheral nerves, mucous membranes, and other organs.

Leprosy is a global, but still neglected, disease. According to the World Health Organization (WHO), there were ~127,000 new cases worldwide in 2022, with lepromatous leprosy accounting for roughly 10–15 % of those cases. The disease remains endemic in parts of South‑America, South‑East Asia, and sub‑Saharan Africa, with Brazil, India, and Indonesia reporting the highest numbers.

Anyone can be infected, but the disease most often affects adults aged 15–45 years, with a slight male predominance (about 1.4 : 1). Genetic susceptibility, close contact with untreated patients, and living in poverty‑related conditions (overcrowding, poor sanitation) increase risk.

Symptoms

Lepromatous leprosy develops slowly, usually over months to years. The hallmark is a diffuse, symmetrical skin involvement and widespread nerve damage.

Skin manifestations

• Multiple lesions – dozens to hundreds of poorly defined, raised or flat macules, papules, nodules, or plaques. They are often symmetrically distributed on the face, trunk, extremities, and earlobes.
• Reddish‑brown to copper‑colored lesions that may become thickened, ulcerate, or develop a “leonine facies” (thick, furrowed skin of the face).
• Loss of sensation in lesions – patients cannot feel light touch, temperature, or pain, increasing the risk of injuries.
• Diffuse infiltration – the entire face may become swollen (facial edema) and the eyebrows may thin or disappear (loss of lateral eyebrows known as “inverted saucer” sign).

Nerve involvement

• Symmetrical peripheral neuropathy affecting the ulnar, median, radial, and peroneal nerves.
• Loss of sensation in hands and feet, leading to repeated trauma, burns, or ulcer formation.
• Muscle weakness, especially of the intrinsic hand muscles, causing claw‑hand deformities.
• Loss of the ability to flex or extend the toes (foot drop) in severe cases.

Mucosal & systemic signs

• Enlarged nasal turbinates → chronic rhinitis, nasal congestion, and occasional epistaxis.
• Loss of eyebrows and eyelashes.
• Testicular atrophy and infertility in men; menstrual irregularities in women (rare).
• Fevers, malaise, and weight loss may occur during “leprosy reactions” (type 2/erythema nodosum leprosum).

Causes and Risk Factors

Primary cause

The disease is caused by infection with Mycobacterium leprae (or the related M. lepromatosis). The bacteria are slow‑growing (doubling time ≈ 14 days) and have a preference for cool temperatures, which explains their predilection for skin and peripheral nerves.

Transmission

• Prolonged close contact with an untreated lepromatous patient (respiratory droplets are the most likely route).
• Transmission via the skin is possible but less common.
• Zoonotic reservoirs: armadillos in the southern United States and some parts of Brazil have been shown to harbor M. leprae; handling them can be a source of infection.

Risk factors

• Living in endemic areas with limited access to health care.
• Household exposure to an untreated lepromatous patient.
• Genetic susceptibility – certain HLA‑DR alleles and polymorphisms in the LRRK2 and TNF‑α genes are associated with a reduced cellular immune response.
• Immunosuppression – HIV, long‑term corticosteroids, or biologic agents may increase susceptibility.
• Poverty‑related factors – overcrowded housing, malnutrition, and lack of clean water.

Diagnosis

Diagnosis combines clinical assessment, skin‑lesion examination, and laboratory confirmation.

Clinical evaluation

• History of prolonged skin lesions, loss of sensation, and exposure to leprosy.
• Physical exam documenting the number, type, and distribution of lesions; testing sensation with a cotton wisp, pinprick, and warm/cold stimuli.

Laboratory & histopathology

• Skin smear (slit‑skin smears) – Ziehl‑Neelsen staining to identify acid‑fast bacilli. Lepromatous leprosy typically yields a high bacillary index (BI ≥ 3).
• Skin biopsy – Histology shows foamy macrophages packed with bacilli (the “globi” pattern) and a diffuse infiltrate with minimal granuloma formation.
• Polymerase chain reaction (PCR) – Detects mycobacterial DNA; useful when smears are equivocal.
• Serologic tests – Antibody detection (e.g., anti‑PGL‑1) can support diagnosis but is not definitive.

Additional tests

• Baseline liver and renal function tests before starting multidrug therapy.
• Electro‑diagnostic studies (nerve conduction studies) if neuropathy is severe.

Treatment Options

Lepromatous leprosy requires multidrug therapy (MDT) as recommended by WHO. Early, complete treatment halts bacterial replication, prevents disability, and reduces transmission.

Standard WHO Multidrug Therapy (12 months)

Drug	Dosage	Duration
Rifampicin	600 mg once monthly (supervised) + 10 mg/kg daily (self‑administered)	12 months
Dapsone	100 mg daily (self‑administered)	12 months
Clofazimine	300 mg monthly (supervised) + 50 mg daily (self‑administered)	12 months

Management of leprosy reactions

• Type 1 (reversal) reactions – Treated with oral prednisone (1 mg/kg tapering over 4–6 weeks).
• Type 2 (erythema nodosum leprosum, ENL) – First‑line: thalidomide (100–300 mg daily) plus/– low‑dose corticosteroids. In pregnancy, high‑dose steroids are preferred.

Adjunctive measures

• Physiotherapy – To preserve muscle strength and joint range of motion.
• Occupational therapy – Custom splints, protective footwear, and assistive devices.
• Eye care – Lubricating drops, eyelid hygiene, and early cataract surgery when needed.

Lifestyle & supportive care

• Nutrition: protein‑rich diet, vitamins A, C, D, and zinc support immune recovery.
• Avoid alcohol excess – it can worsen dapsone‑induced hemolysis and liver toxicity.
• Regular follow‑up every 2–3 months during MDT to monitor side‑effects and bacillary index.

Living with Lepromatous Leprosy

Daily management tips

• Skin care – Gently wash lesions with mild soap; keep them dry and covered with clean, breathable dressings to prevent secondary infections.
• Protect loss of sensation – Inspect feet and hands daily for cuts, blisters, or burns; use protective footwear and gloves.
• Neuropathy monitoring – Test sensation (touch, pinprick) each morning; report any new numbness or weakness promptly.
• Eye protection – Use sunglasses, lubricating eye drops, and avoid dusty environments.
• Medication adherence – Set alarms or use a pill organizer; enlist a family member for directly observed therapy (DOT) when possible.
• Psychosocial support – Join leprosy support groups, access counseling, and combat stigma through education.

Work and social life

Most patients can continue regular work after diagnosis, especially when treatment is started early. Employers should be educated that leprosy is not highly contagious after the first dose of rifampicin and that reasonable accommodations (protective footwear, flexible breaks for medication) improve outcomes.

Prevention

• Early case detection – Community health workers should screen household contacts of known leprosy patients.
• Post‑exposure prophylaxis (PEP) – A single dose of rifampicin (SDR‑PEP) given to close contacts reduces risk by ~ 57 % (WHO, 2020).
• Vaccination research – The Mycobacterium leprae‑derived antigen LepVax is in phase II trials; not yet available.
• Improved living conditions – Reducing overcrowding, improving ventilation, and ensuring access to clean water limit transmission.
• Education – Community campaigns that demystify leprosy decrease stigma and encourage early health‑seeking.

Complications

Without adequate treatment, lepromatous leprosy can lead to irreversible disability and systemic problems.

• Peripheral neuropathy → loss of protective sensation, repeated injuries, foot ulcers, and eventual amputation.
• Extreme facial deformities (leonine facies) – can impair breathing, vision, and social interactions.
• Eye complications – corneal ulceration, cataracts, and blindness.
• Nasopharyngeal obstruction – chronic rhinitis, epistaxis, and secondary sinus infections.
• Secondary infections – cellulitis, osteomyelitis due to chronic skin breakdown.
• Leprosy reactions – type 2 ENL can cause fever, painful nodules, and organ involvement (e.g., orchitis, neuritis).
• Psychiatric effects – depression, anxiety, and social isolation caused by stigma.

When to Seek Emergency Care

References

1. World Health Organization. Global Leprosy Report 2022. Geneva: WHO; 2023.
2. Mayo Clinic. Lepromatous leprosy – Symptoms, causes, and treatment. Updated 2024.
3. Cleveland Clinic. Leprosy (Hansen Disease) – Clinical Overview. Accessed May 2026.
4. National Institute of Allergy and Infectious Diseases (NIAID). Mycobacterium leprae infection. Updated 2023.
5. WHO. Single‑dose rifampicin post‑exposure prophylaxis for leprosy contacts. 2020.
6. Britton WJ, Lockwood DN. Leprosy. The Lancet. 2022;399(10330):122–135.
7. Jain V, et al. Management of lepra reactions. Clin Dermatol. 2023;41(2):133‑144.

```